Lumos Pharma | NLNK - Ativo Circulante



Ativo Circulante Alterar Data
Agenus USD 78.81M 16.47M 2026-06
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Capricor Therapeutics USD 242.13M 40.96M 2026-06
Celldex Therapeutics USD 724.93M 265.71M 2026-06
Cipla INR 241.47B 7.71B 2026-03
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 137.28M 10.74M 2026-03
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 64.67B 9.84B 2026-06
Grifols EUR 5.96B 316.31M 2025-12
Incyte USD 6.03B 542.31M 2026-06
Intrexon USD 23.72M 45.04M 2024-06
Merck USD 36.68B 1.66B 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Pfizer USD 41.36B 1.46B 2026-06
Prothena USD 292.01M 47.19M 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06